Treatment mechanism and research progress of bevacizumab for glioblastoma.

IF 3.6 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2025-04-25 eCollection Date: 2025-01-01 DOI:10.62347/RNUE7193

Xinliang Liu, Zhigang Chen, Pengwei Yan, Tao Yang, Dan Zong, Wenjie Guo, Xia He

{"title":"Treatment mechanism and research progress of bevacizumab for glioblastoma.","authors":"Xinliang Liu, Zhigang Chen, Pengwei Yan, Tao Yang, Dan Zong, Wenjie Guo, Xia He","doi":"10.62347/RNUE7193","DOIUrl":null,"url":null,"abstract":"<p><p>Hypervascularization is a notable pathological hallmark of glioblastoma (GBM). Bevacizumab (Bev) remains the sole antiangiogenic agent approved by the U.S. Food and Drug Administration (FDA) for GBM treatment. The approval for this indication was supported by several phase II studies demonstrating that Bev significantly improved progression-free survival and the best imaging response in patients with recurrent GBM. Three large phase III randomized controlled trials reported that Bev did not significantly extend overall survival (OS). Nevertheless, Bev has been shown to delay the deterioration of patients' quality of life by postponing tumor progression. This review synthesizes findings from recent investigations exploring Bev in combination with targeted therapies, immunotherapy, or reirradiation. Additionally, this review discusses dosing regimens, administration, treatment failure patterns, third-line therapeutic applications, and prognostic markers of Bev. By synthesizing current evidence, this review aims to inform clinical decision-making for neuro-oncology clinicians.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 4","pages":"1874-1901"},"PeriodicalIF":3.6000,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12070100/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/RNUE7193","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hypervascularization is a notable pathological hallmark of glioblastoma (GBM). Bevacizumab (Bev) remains the sole antiangiogenic agent approved by the U.S. Food and Drug Administration (FDA) for GBM treatment. The approval for this indication was supported by several phase II studies demonstrating that Bev significantly improved progression-free survival and the best imaging response in patients with recurrent GBM. Three large phase III randomized controlled trials reported that Bev did not significantly extend overall survival (OS). Nevertheless, Bev has been shown to delay the deterioration of patients' quality of life by postponing tumor progression. This review synthesizes findings from recent investigations exploring Bev in combination with targeted therapies, immunotherapy, or reirradiation. Additionally, this review discusses dosing regimens, administration, treatment failure patterns, third-line therapeutic applications, and prognostic markers of Bev. By synthesizing current evidence, this review aims to inform clinical decision-making for neuro-oncology clinicians.

查看原文本刊更多论文

贝伐单抗治疗胶质母细胞瘤的机制及研究进展。

血管增生是胶质母细胞瘤（GBM）的显著病理特征。贝伐单抗（Bevacizumab, Bev）仍然是美国食品和药物管理局（FDA）批准用于GBM治疗的唯一抗血管生成药物。该适应症的批准得到了几项II期研究的支持，这些研究表明，Bev显著提高了复发性GBM患者的无进展生存期和最佳影像学反应。三个大型III期随机对照试验报告Bev没有显著延长总生存期（OS）。然而，Bev已被证明通过延缓肿瘤进展来延缓患者生活质量的恶化。这篇综述综合了最近关于Bev联合靶向治疗、免疫治疗或再照射的研究结果。此外，本综述还讨论了Bev的给药方案、给药、治疗失败模式、三线治疗应用和预后标志物。通过综合目前的证据，本综述旨在为神经肿瘤学临床医生提供临床决策信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.